~~<i id='9A3DF30917'><strike id='9A3DF30917'><tt id='9A3DF30917'><pre id='9A3DF30917'></pre></tt></strike></i>~~

Home» explore» Wikipedia

Wikipedia

author：knowledge 2025-09-06 07:11:59 Page View：74

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Why Congress must ban federal programs from using QALYs
Next article： Novavax promises a turnaround & Lilly roils the obesity market

Wikipedia

The cancer drug shortage isn’t new — and neither are the solutions

PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

Grail's uphill battle for Medicare to cover its cancer screening test

GrailWASHINGTON—GrailisaggressivelylobbyingtogetMedicaretopayforitscancer-screeningtestGalleri—butex

Medical leaders decry Supreme Court decision on affirmative action

STEFANIREYNOLDS/AFPviaGettyImagesMedicalleadersonThursdayreactedswiftlytotheSupremeCourt’sdecisionto

Companies helping big Covid

AdobePfizerandModernaaren’ttheonlyvaccinemoney-makers.MuchoftherevenueandprofitsfromCovid-19vaccines